Shared by
Aaron-Roth
Ampio Pharma reports positive results for both primary and secondary endpoints of pivotal Phase 3 trial of Ampion in severe osteoarthritis of the knee (1.75)
Ampion met its primary endpoint with 71% of Ampion treated patients meeting the OMERACT-OARSI responder criteria, which exceeds the physician reported threshold of 30% for a meaningful treatment in severe osteoarthritis of the knee (p < 0.001).
Ampion is the first therapy indicated for signs and symptoms for severe osteoarthritis of the knee and will address a significant treatment gap.
Conference call, December 14, at 8:30 ET
Execution detail:
| Date/time | Symbol | Side | Price | Position |
|---|---|---|---|---|
| 2017-12-14 09:39:23 | AMPE | sell | $2.440 | short |
| 2017-12-14 09:42:05 | AMPE | sell | $2.490 | short |
| 2017-12-14 09:42:11 | AMPE | sell | $2.550 | short |
| 2017-12-14 09:47:56 | AMPE | buy | $2.410 | short |
| 2017-12-14 09:49:30 | AMPE | buy | $2.340 | short |
| 2017-12-14 09:55:14 | AMPE | buy | $2.400 | 0 |
| 2017-12-14 10:09:51 | AMPE | sell | $2.770 | short |
| 2017-12-14 10:12:11 | AMPE | sell | $2.770 | short |
| 2017-12-14 11:23:47 | AMPE | buy | $2.620 | short |
| 2017-12-14 12:06:12 | AMPE | buy | $2.320 | 0 |
Leave a comment about this trade!
You need to log into your Tradervue account to leave a comment. If you don't have one,
it takes
just a few seconds to sign up, and it's free!